江苏集萃药康生物科技股份有限公司（以下简称"公司"）于 2024 年 10 月 29 日召开第二届董事会第八次会议，审议通过了《关于以集中竞价交易方式回购公 司股份方案的议案》，同意公司使用自有资金和股票回购专项贷款资金以集中竞价 方式回购公司股份，回购股份将用于员工持股计划或股权激励，回购股份的资金 总额不低于人民币 2,200 万元（含），不超过人民币 4,000 万元（含），回购股份的 价格不超过人民币 18 元/股（含），回购股份的期限自董事会审议通过本次回购股 份方案之日起 12 个月内。具体内容详见公司分别于 2024 年 10 月 31 日、2024 年 11 月 8 日在上海证券交易所网站（www.sse.com.cn）上披露的《江苏集萃药康生 物科技股份有限公司关于以集中竞价交易方式回购公司股份方案的公告》及《江 苏集萃药康生物科技股份有限公司关于以集中竞价交易方式回购公司股份的回购 报告书》。 二、回购股份的进展情况 证券代码：688046 证券简称：药康生物 公告编号：2025-045 江苏集萃药康生物科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事 ...

Meeting Overview - The annual general meeting of Jiangsu Jicui Yaokang Biotechnology Co., Ltd. was held with no rejected proposals [2] - The meeting was convened by the board of directors and chaired by Chairman Gao Xiang, utilizing a combination of on-site and online voting [2] Attendance - All 9 current directors attended the meeting [3] - All 3 current supervisors were present [3] - The board secretary and CFO, Wang Yihou, also attended the meeting [3] Resolutions Passed - The following proposals were approved during the meeting: 1. 2024 Annual Report and its summary [4] 2. 2024 Board of Directors' Work Report [4] 3. 2024 Supervisory Board Work Report [5] 4. 2024 Financial Settlement Report [5] 5. 2025 Financial Budget Report [5] 6. 2024 Profit Distribution Proposal [5] 7. Reappointment of the auditing firm for 2025 [5] 8. Compensation for directors and supervisors for 2025 [5] 9. Use of raised funds to permanently supplement working capital [5] 10. Expansion of business scope and amendments to the Articles of Association [6] Voting Details - Proposals 1 to 9 were passed with more than half of the voting rights present [6] - Proposal 10 was passed with more than two-thirds of the voting rights present [6] - Separate counting was conducted for proposals 6, 7, 8, and 9 concerning minority investors [6] Legal Verification - The meeting was witnessed by Jiangsu Century Tongren Law Firm, with lawyers confirming the legality of the meeting's procedures and resolutions [6]

Meeting Overview - The shareholders' meeting of Jiangsu Jicui Yaokang Biotechnology Co., Ltd. was held on May 28, 2025, in Nanjing [1] - A total of 38 ordinary shareholders attended, holding 215,128,854 voting rights, which accounts for 52.8039% of the company's total voting rights [1] Voting Results - All proposed resolutions were approved with significant majority votes, including: - Resolution 1: 99.8955% in favor, 0.0998% against, and 0.0047% abstained [1] - Resolution 2: 99.8957% in favor, 0.0995% against, and 0.0048% abstained [1] - Resolution 3: 99.8955% in favor, 0.0998% against, and 0.0047% abstained [1] - Resolution 4: 99.8938% in favor, 0.1014% against, and 0.0048% abstained [2] Shareholder Composition - The meeting included various categories of shareholders, with a notable presence of those holding less than 5% of shares, which accounted for 98.7830% in favor of the resolutions [3] - The voting rights of shareholders with a market value below 500,000 were also represented, indicating broad participation [3] Legal Compliance - The meeting's procedures and voting processes were confirmed to be in compliance with the Company Law and relevant regulations, ensuring the legality and validity of the resolutions passed [3][4]

证券代码：688046 证券简称：药康生物 公告编号：2025-044 江苏集萃药康生物科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 28 日 （二） 股东大会召开的地点：南京市江北新区学府路 12 号 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 38 | | --- | --- | | 普通股股东人数 | 38 | | 2、出席会议的股东所持有的表决权数量 | 215,128,854 | | 普通股股东所持有表决权数量 | 215,128,854 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 52.8039 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 52.8039 | （四） 表决方式是否符 ...

法律意见书 江苏集萃药康生物科技股份有限公司: 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民 共和国证券法》《上市公司股东会规则》和《上海证券交易所科创板上市公司自 律监管指引第1号 -- 规范运作》等法律、法规和规范性文件以及《公司章程》 的规定,本所受公司委托,指派本所律师出席公司 2024年年度股东大会,并就 本次股东大会的召集、召开程序、出席会议人员资格、召集人资格、表决程序以 及表决结果的合法有效性等事项出具法律意见。 为出具本法律意见书,本所律师对本次股东大会所涉及的有关事项进行了审 查,查阅了相关会议文件,并对有关问题进行了必要的核查和验证。 本所律师同意将本法律意见书随公司本次股东大会决议一并公告,并依法对 本法律意见书承担相应的责任。 江苏世纪同仁律师事务所 关于江苏集萃药康生物科技股份有限公司 2024 年年度股东大会的 本所律师根据相关法律、法规和规范性文件的要求,按照律师行业公认的业 务标准、道德规范和勤勉尽责精神,出具法律意见如下: 一、关于本次股东大会的召集、召开程序 1、本次股东大会的召集 本次股东大会由董事会召集。 2025年4月24日,公司召开了第二届董 ...

Core Insights - The total margin financing balance on the STAR Market decreased by 66.25 million yuan compared to the previous trading day, with a total balance of 152.028 billion yuan as of May 27 [1][2] Financing Balance Summary - The highest financing balance on the STAR Market is held by SMIC, with a latest balance of 7.317 billion yuan, followed by Cambrian and Haiguang Information with balances of 4.348 billion yuan and 3.240 billion yuan respectively [1] - A total of 280 stocks saw an increase in financing balance, while 303 stocks experienced a decrease [1] - The stocks with the largest increase in financing balance include Aikasebo (52.57%), Kejie Intelligent (38.44%), and Wandesi (17.02%), while the largest decreases were seen in Jingpin Special Equipment (-23.58%), Weide Information (-18.44%), and Liyang Chip (-18.08%) [1] Securities Lending Balance Summary - The highest securities lending balance is also held by SMIC, with a latest balance of 2.5 million yuan, followed by Haiguang Information and Cambrian with balances of 1.9 million yuan and 1.6 million yuan respectively [2] - A total of 123 stocks saw an increase in securities lending balance, while 142 stocks experienced a decrease [2] - The stocks with the largest increase in securities lending balance include Yaokang Biological (424.49%), Lianying Laser (407.58%), and Nami Technology (49.43%), while the largest decreases were seen in Haiyou New Materials (-71.28%), Fangbang Co. (-66.42%), and Zhenhua New Materials (-43.34%) [2]

Core Viewpoint - Jiangsu Jicui Yaokang Biotechnology Co., Ltd. has announced the cancellation of certain unvested restricted stocks granted under its 2022 incentive plan due to the departure of three incentive recipients, adjusting the total number of recipients and shares accordingly [1][4][5] Group 1: Decision Process and Disclosure - The company has completed the necessary decision-making procedures and disclosed information regarding the 2022 restricted stock incentive plan [1] - Independent directors provided opinions on the incentive plan proposals, and the supervisory board verified the related matters [1][3] Group 2: Specifics of Stock Cancellation - The cancellation of restricted stocks was due to the departure of three incentive recipients, leading to a reduction in the number of initial recipients from 17 to 14 [4][5] - The total number of restricted stocks granted was adjusted from 962,000 shares to 872,000 shares, resulting in the cancellation of 90,000 shares [5] Group 3: Impact on the Company - The cancellation of these restricted stocks is not expected to have a significant impact on the company's operational situation or the stability of its technical and management teams [5] - The ongoing implementation of the stock incentive plan remains unaffected by this cancellation [5] Group 4: Supervisory Board and Legal Opinions - The supervisory board agrees that the cancellation of unvested restricted stocks complies with relevant laws and regulations, and does not harm shareholder interests [5] - Legal opinions confirm that the cancellation has obtained necessary approvals and aligns with applicable regulations [5]

Group 1 - The company held its 10th meeting of the second Supervisory Board on May 22, 2025, with all three attending supervisors present, ensuring compliance with relevant laws and regulations [1][2] - The Supervisory Board approved the proposal to cancel part of the granted but unvested restricted stock, confirming it aligns with legal regulations and does not harm shareholder interests [1][2] - The proposal to adjust the grant price of the 2022 restricted stock incentive plan was also approved, following the completion of the company's 2023 and 2024 annual equity distributions [2][3] Group 2 - The Supervisory Board agreed that the second vesting period conditions for the initial grant of the 2022 restricted stock incentive plan have been met, allowing eligible participants to process the vesting of their restricted stock [3] - The adjustment of the 2025 stock appreciation rights incentive plan regarding the number of participants and quantity was approved, confirming compliance with relevant regulations [3][4] - The proposal to grant stock appreciation rights to eligible participants under the 2025 incentive plan was unanimously approved, with the grant date set for May 22, 2025 [4]

Group 1 - The financial director of Jiangsu Jicui Yaokang Biotechnology Co., Ltd., Xu Chongbo, has resigned due to personal reasons and will no longer hold any position in the company after his resignation takes effect [1] - The company expressed gratitude for Xu Chongbo's contributions during his tenure [1] Group 2 - Wang Yiou has been appointed as the new financial director, concurrently serving as the board secretary, effective from the date of the board's approval [1] - Wang Yiou holds a master's degree in finance from the University of Illinois at Urbana-Champaign and has prior experience in strategic investment and capital operations [2] - As of the announcement date, Wang Yiou does not hold any shares in the company and meets all legal and regulatory requirements to serve as a senior management member [2]

江苏集萃药康生物科技股份有限公司 2025 年股票增值权激励计划激励对象名单（截至授予日） 激励对象获授的股票增值权分配情况： | 职务 | | 获授的股票增 值权数量 | 占本激励计划拟授 | 占公司授予日 | | --- | --- | --- | --- | --- | | | | （万份） | 出权益数量的比例 | 股本总额比例 | | 核心骨干员工（外籍 25 | 人） | 43.60 | 79.85% | 0.11% | 注：1、上述任何一名激励对象通过全部在有效期内的股权激励计划获授的本公司股票均未超过公司总 股本的 1%。公司全部在有效期内的激励计划所涉及的标的股票总数累计不超过股权激励计划提交股东大会 审议时公司股本总额的 20%。 2、本激励计划激励对象不包括公司独立董事、监事。 3、上表中数值若出现总数与各分项数值之和尾数不符，均为四舍五入原因所致。 江苏集萃药康生物科技股份有限公司董事会 2025 年 5 月 22 日 1 ...